Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 533M | 1% |
| Gross Profit | 119M | 6.6% |
| Cost of Revenue | 414M | 0.5% |
| Operating expense | 50M | 18.6% |
| Net Income | 96M | 9.1% |
| EBITDA | 113M | 6.8% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 2.08B | 8.5% |
| Total Liabilities | 1.2B | 4% |
| Total Equity | 881M | 15.4% |
| Shares Outstanding | 31M | 0.3% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | 149M | 28.1% |
| Cash from investing | -10M | 18% |
| Cash from financing | 6.3M | 842% |
EPS
Financial Highlights for Medpace in Q3 '24
Medpace reported a revenue of 533M, which is a 1% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 119M, marking a 6.6% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 414M, a -0.5% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 50M, showing a 18.6% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 96M, showing a 9.1% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 113M, showing a 6.8% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Medpace with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
